According to GlobalData’s medical device pipeline database, 71 Prenatal Screening devices are in various stages of development globally. GlobalData’s report Prenatal Screening provides an overview of the segment’s pipeline landscape and offers detailed analysis of its products. Buy the report here.

Smarter leaders trust GlobalData

Of these devices, 43 are in active development, while the remaining 28 are in an inactive stage of development. There are 20 products in the early stages of development, and the remaining 23 are in the late stages of development.

In Vitro Diagnostics (IVD) include reagents, instruments and systems intended for use in the diagnosis of disease or other conditions, including the determination of the state of health, in order to treat or prevent disease. Prenatal screening is a set of tests that are offered to pregnant women to help identify potential health problems in the fetus. Prenatal screening describes tests that detect potential problems that affect the viability and development of the fetus using both less invasive and more invasive sampling techniques. There are two main types of prenatal screening: screening tests and diagnostic tests. This market includes the sub-segments Free Beta Human Chorionic Gonadotropin (hCG) Tests, Pregnancy Associated Plasma Protein A (PAPP-A) Tests, Total Human Chorionic Gonadotropin (hCG) Tests, Unconjugated Estriol (uE3) Tests, Alpha-Fetoprotein (AFP) Tests, and Inhibin A Tests.

Innovations in the medical devices sector are linked to the development of new approaches, processes, or technologies for treating, diagnosing, and managing disease in response to demand from healthcare for better patient outcomes and reduce healthcare costs.

Based on an analysis of GlobalData’s Medical Intelligence Center pipeline product database, these actively developed Prenatal Screening pipeline devices are all expected to be approved within the next ten years.

Currently, private organizations, public entities and institutions are working on the development of Prenatal Screening devices. Overall, most of these Prenatal Screening pipeline devices are being developed by private entities.

Key players involved in the active development of Prenatal Screening include Chinese University of Hong Kong, Chinese University of Hong Kong, Siemens Healthineers, Sera Prognostics, Shenzhen Mindray Bio-Medical Electronics, Roche Diagnostics International, Mirvie, Illumina, INEX Innovate and Intignus Biotech.

For a complete picture of the developmental pipeline for Prenatal Screening devices, buy the report here.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

The medical devices pipeline data used in this article were obtained from the Medical Pipeline Products Database of GlobalData’s Medical Intelligence Center. The Pipeline Products database is a is a comprehensive source of information on medical devices, it covers 39K products which are in development stage and intended for diagnosis, treatment, and management of diseases/conditions/symptoms directly or indirectly. The pipeline products included in the database are sourced from reliable and authenticated sources, such as company websites, SEC filings, conference presentations, analyst presentations, news releases, clinical trial registries, and grants. The information is collected by following systematic research techniques and proprietary methodology.